Healthcare Industry News: ACell
News Release - April 24, 2013
ACell MatriStem(R) Products Demonstrated to be Effective on Hard to Heal WoundsCOLUMBIA, Md., April 24, 2013 -- (Healthcare Sales & Marketing Network) -- ACell MatriStem® medical devices were featured in a peer-reviewed article, "Porcine Urinary Bladder matrix: a Retrospective Study and Establishment of Protocol," published in the October, 2012 issue of the Journal of Wound Care (www.journalofwoundcare.com). Analysis showed a decrease in mean closure time after application of MatriStem in wounds that had received previous applications of other advanced wound care products. All wounds utilizing MatriStem achieved complete closure including those with exposed bone, tendon, and joint closure in the thirty-four patient study. In the study MatriStem was shown to be a novel advanced wound care modality in the treatment of complex lower extremity diabetic, venous insufficient, ischemic and decubitus ulcers.
Patients were treated with MatriStem medical devices, the only commercially available form of urinary bladder matrix (UBM), at the Eastern Colorado Health Care System, Veterans Affairs (VA) Medical Center in Denver, CO. The study was independent in nature. No external sources of funding for this study were received by the authors or the VA. The authors had no conflicts of interest to declare.
"We are very satisfied with the results of this independent study on non-healing wounds. MatriStem has shown to be effective where other products fail," Rodney Bosley, ACell President & COO said. "Results like these have established ACell as a leader in Regenerative Medicine."
MatriStem medical devices are porcine-derived extracellular matrix (ECM) that maintain and support a healing environment through constructive remodeling, and are available in particle and sheet forms by prescription only. Refer to IFU supplied with each device for indications, contraindications, and precautions.
ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. ACell's patented ECM medical devices address important clinical needs, while providing safe, effective, economical and therapeutic outcomes to the wound care and surgical communities. These devices, trademarked as MatriStem, are appropriate for acute wounds, chronic wounds and various surgical procedures. All MatriStem devices are made in the USA. For more information, call (800) 826-2926 or visit www.acell.com.
Source: ACell Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.